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Purpose: Dendritic cell (DC)-based tumor vaccine is an attractive modality for the treat-
ment of hormone-refractory prostate cancer (HRPC) because it has some efficacy and 
few side effects in patients with poor general conditions. The aim of this study was to 
establish which is the most effective DC vaccine for the treatment of HRPC. We com-
pared DC vaccine sensitized with tumor lysate and a fusion vaccine of DCs and tumor 
cells.
Materials and Methods: The DU145 cancer cell line was purchased from the American 
Type Culture Collection. DCs were cultured from peripheral blood monocytes. 
Peripheral blood monocytes were cultured in RPMI 1640 medium supplemented with 
interleukin-4 (IL-4), granulocyte-macrophage colony-stimulating factor, and 10% fetal 
calf serum. Tumor necrosis factor-alpha was added on day 7 to support maturation. 
Functional activity was measured in three groups: the DC single-culture group, the 
DC culture group with DC vaccine sensitized with tumor lysates, and the DC culture 
group prepared with tumor fusion vaccine made from irradiated tumor cells and mono-
cyte-derived DCs by the polyethylene glycol method.
Results: By FACS analysis, the rate of DC-tumor fusion vaccine was 20.3±3%. The IL-12 
level produced by the DC-tumor fusion vaccine was significantly higher than that of 
DCs pulsed with tumor lysate (p＜0.05). Also, the generation of interferon-γ by tu-
mor-specific T cells in the DC-tumor fusion vaccine group was superior to that of DCs 
pulsed with tumor lysate (p＜0.05). In addition, the T cells of the tumor lysate-pulsed 
DCs and tumor fusion vaccine had 1.6 and 2.5 times the functional activity, respectively, 
of the DC single-culture group in killing tumor cells in the cytotoxicity assay.
Conclusions: The DC-tumor fusion vaccine seems to be more effective than DC sin-
gle-culture or DC-tumor lysate vaccine in the treatment of HRPC.
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INTRODUCTION
According to recent survival data for Korea, cancer-specific 
survival rates are 57.8%, 16.8%, and 10.1% in the 1st, 3rd, 
and 5th year, respectively, in patients with hormone re-
fractory prostate cancer (HRPC) [1]. Dendritic cells are the 
strongest antigen-presenting cells. With the latest ad-
vances in immunology, new treatment methods using den-
dritic cells (DCs) have been proposed [2]. DCs stimulate not 
only memory T cell but also naive T cells and thereby induce 
appropriate immune responses [3]. For immunotherapy 
with DCs, the DCs should be sensitized before infusion to 
amplify their anti-cancer effects, which are specific to the 
corresponding tumor. Tumor antigens that are used for DC 
sensitization include peptides, proteins, DNA and RNA 
coding these antigens, and tumor lysates, which amplify 
the anti-cancer effects specific to the corresponding tumor 
before infusion. T cell reactions to sensitized DCs have been 
reported by many authors using various types of tumor 
cells [2,4-11]. Galea-Lauri et al reported that the immune 
responses occurring due to sensitization with a single anti-
gen had a lower or a restricted degree of efficacy compared Korean J Urol 2010;51:139-144
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with tumor fusion vaccines [12].
　DCs can be produced by culturing and proliferating mon-
ocytes that are extracted from the peripheral blood of nor-
mal healthy people. In the current study, we compared the 
feasibility and efficacy of DC fusion vaccines with those of 
DC only or DC sensitized with tumor lysate.
MATERIALS AND METHODS
1. Cell lines and cell culture
The hormone-refractory cell line DU145 was purchased 
from the American Type Culture Collection (Rockville, 
USA). RPMI 1640 (Gibco, Grand Island, USA), 10% fetal 
calf serum (FCS; Invitrogen, Carlsbad, USA), 100 units/ml 
penicillin, and 100 ug/ml penicillin- streptomycin solution 
(Gibco) were added as the basal medium for the culture of 
the DU145 cell line. The cells were cultured in an incubator 
at 37
oC and 5% CO2 by use of conventional cell culture 
methods.
2. Production of DCs and T-lymphocytes from peripheral 
blood mononuclear cells
1) Monocyte extraction and production of DCs: Monocytes 
were isolated from peripheral blood mononuclear cells by 
density-gradient centrifugation with Ficoll-Hypaque 
(Pharmacia, Uppsala, Sweden). The monocytes were cul-
tured in RPMI 1640 medium to which 10% FCS was added 
at 37
oC for 2 to 3 hours. Then, the supernatant cells (T cells) 
were placed in a medium containing 90% heat-inactivated 
FCS to which 10% dimethyl sulfoxide (Sigma-Aldrich 
Corp., St. Louis, USA) was added.
　The monocytes remaining on the floor of the flask were 
cultured in RPMI 1640 medium to which 40 ng/ml inter-
leukin-4 (IL-4), 50 ng/ml granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), and 10% FCS were 
added. A fresh medium to which cytokines were added was 
additionally provided at a 2-day interval. Tumor necrosis 
factor-alpha; 50 ng/ml; Centus Corporation, Emmeryville, 
USA) was added on day 7 after culture.
2) Characterization of DC phenotype: After culture, DCs 
were collected and then photographed by light microscopy. 
To examine the immune phenotypes, the cell surface was 
coated with antibodies such as CD3, CD83, and CD86, 
which were labeled with fluorescein isothiocyanate (FITC) 
and phycoerythrin (PE). This was followed by flow cy-
tometry (Epics WL, Beckman Coulter, Brea, CA, USA).
3. Acquisition of cells fused with tumor cells
1) Induction of apoptosis of the HRPC cell line: To assist 
in the cell fusion, the cell line was irradiated with 150 Gy 
to induce apoptosis. After a 24-hour culture, the sample 
was used for the fusion.
2) Measurement of the degree of apoptosis: Apoptosis of the 
HRPC cell line was assessed by the Annexin V binding as-
say kit. Cells were stained with FITC-Annexin V (BD- 
PharMingen, San Diego, USA) and propidium iodide (PI, 
10 g/ml, Sigma). Cells undergoing early apoptosis were de-
termined as the percentage of Annexin V＋/PI− cells by 
FACScan with the Cell Quest 1.0 software package (BD, 
San Diego, USA).
3) Acquisition of fusion vaccines between DCs and tumor 
cells: Methods for fusing the nondependent prostate cancer 
cell line with DCs were based on the polyethylene glycol 
(PEG)-fusion protocol. DCs and the prostate cancer cell line 
were stained with cell marker materials, CD86-FITC and 
PKH-26-PE, respectively. Then, the cells were mixed at a 
ratio of 1:2. According to the PEG-fusion protocol, 1 ml of 
PEG 1500 (Applied Science, Penzberg, Germany) that was 
previously heated was added at 37
oC for 3 minutes, and 14 
ml of PEG 1500 was additionally placed in a fusion medium, 
which was cultured at 37
oC. The fusion rate of the fusion 
vaccine (CD86-FITC/PKH-26-PE) was measured by FACS 
analysis.
4. Sensitization of DCs using freeze-thaw tumor lysate
Briefly, DU-145 cells (2x10
6 cells/ml) were frozen at −80
oC 
for 20 min and were then thawed at 37
oC for 10 min. After 
three freeze-thaw cycles, the lysate was divided into ali-
quots and incubated with 1x10
6 DCs (lysate:DC ratio=3 tu-
mor cells:DCs) overnight at 37
oC in complete media.
5. Acquisition of T-lymphocytes
To acquire tumor-specific T-lymphocytes, the reaction was 
performed for T-lymphocytes corresponding to 10 to 50 
times the number of DCs. Then, the sample was cultured 
in an X-vivo 15 medium (Bio Whittaker, Walkersville, 
USA) to which 20 ng/ml IL-7 and 100 pg/ml IL-12 (R&D 
Systems Inc., Minneapolis, USA) were added. On day 8, the 
reaction was performed again in an X-vivo 15 medium. 
Thereafter, on day 10, 20 IU/ml IL-2 was added. On day 10 
after culture, T-lymphocytes were isolated and used for fur-
ther laboratory procedures.
6. Measurement of T cell reactions of tumor-fused DCs
1) Analysis of lymphocytic functions (mixed lymphocyte re-
action): To analyze the functions of T-lymphocytes, T cells 
were placed in a 96-well plate at a fixed concentration of 
1x10
5/well. Then, DCs were divided into the following 
groups:
　Group 1, in which only DCs were added with T-lympho-
cytes in identical numbers; Group 2, in which DCs sensi-
tized with tumor lysates were added with T-lymphocytes 
in identical numbers; and Group 3, in which DCs prepared 
with tumor fusion vaccines were added with T-lympho-
cytes in identical numbers. The cells were cultured in me-
dium containing 10% FCS/RPMI, 400 ng/ml GM-CSF, and 
16 ng/ml IL-4 for five days. After the addition of 5-bro-
mo-2-deoxyuridine (BrdU), each well was isolated. The 
fused BrdU was measured by colorimetry.
2) Measurement of cytokines: IL-12 and interferon-gamma 
(IFN-γ) were measured by ELISA (Mabtech AB, Stock-
holm, Sweden). ELISA was performed in accordance with 
the manufacturer’s instructions. Quantification was per-
formed by using a VERSAmax microplate reader (Molecu-Korean J Urol 2010;51:139-144
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FIG. 1. Photograph of dendritic cells on day 7. Aggregates of 
dendritic cells developed from adherent peripheral blood mono-
cytes under the influence of GM-CSF and IL-4 (x1,200, PENTAX
A10, Pentax Corporation, Japan, OLYMPUS CK2, Olympus 
Optical Co., Ltd. Japan). GM-CSF: granulocyte-macrophage 
colony-stimulating factor, IL-4: interleukin-4.
FIG. 3. Efficacy of PEG hybridization of dendritic cells and the 
DU145 tumor cell line. Before hybridization, tumor cells were 
stained with PKH26PE and DCs were stained with monoclonal
antibody against CD86FITC. FACS analysis showed that 20.3%
of DC-tumor hybrids were obtained (circled area). Tumor cells 
were irradiated at 150 Gy and pooled with mature DCs at a 1:2 
ratio. DC: dendritic cell.
FIG. 2. Phenotypic characterization of immature and mature DCs by flow cytometry. (A) Phenotypes of immature DCs. (B) Phenotypes
of mature DCs. Immature dendritic cells were generated from peripheral blood mononuclear cells (PBMCs) of healthy donors by 
culturing with IL-4 and GM-CSF. Differentiation into mature DCs was achieved by the addition of inflammatory cytokine cocktail for
24 hours. Mature DCs have a higher CD83 and CD86 count than do immature DCs. DCs: dendritic cells, IL-4: interleukin-4, GM-CSF: 
granulocyte-macrophage colony-stimulating factor.
lar Devices Corp., Sunnyvale, USA).
3) Measurement of cytotoxicity: Cytotoxicity was meas-
ured in the three previously mentioned groups. In each 
group, the cells were placed in a 96-well plate, and the 
DU145 cell line was placed and cultured at 37
oC for 24 
hours. Then, lactate dehydrogenase (LDH) that was leaked 
from the cell membrane of ruptured tumor cells was meas-
ured by use of the CytoTox-ONE assay (Promega Corp., 
Madison, USA).Korean J Urol 2010;51:139-144
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FIG. 4. Mixed lymphocyte reaction of tumor lysate-pulsed DCs 
and DC-tumor hybrid. Cells were co-cultured with 10
5 allogenic
T cells/well in 96-well plates for 5 days. For 15-20 hours before 
harvesting, 1 uCi of H
3-thymidine was added to each well. Cells
were harvested and incorporated BrdU was measured colori-
metrically (
a: p＜0.05). DC: dendritic cell.
FIG. 5. Dendritic cell function estimated by IL-12 assay. Super-
natants from tumor lysate-pulsed DCs and DC-tumor hybrid 
were analyzed for production of IL-12 by ELISA (
a: p＜0.05). DC:
dendritic cell, IL-12: interleukin-12.
FIG. 6. Generation of IFN-γ-producing tumor-specific T cells. T 
cells re-stimulated by co-culture with tumor lysate-pulsed DCs 
and DC-tumor hybrid were analyzed for production of IFN-γ by
ELISA (
a: p＜0.05).  IFN-γ: interferon-gamma, DC: dendritic cell.
FIG. 7. Generation of cytotoxicity of tumor lysate-pulsed DCs 
and DC-tumor hybrid. T cells stimulated by DC cells pulsed with
DU145 tumor lysate and DC/DU145 hybrid cells were co- 
cultured with DU145 cells in a 96-well plate for 24 hours at 37
oC. 
The CytoTox-ONE assay measured the release of lactate dehy-
drogenase (LDH) from cells with a damaged membrane (
a: p＜
0.05). DC: dendritic cell.
7. Statistical analysis
Statistical analysis of mean values that were calculated 
from the five normal experimental sessions was performed 
by using Student's t test. A value of p＜0.05 was considered 
statistically significant.
RESULTS
1. Acquisition of DCs and confirmation of the phenotype of 
mature DCs 
Inverted light microscopy identified the presence of DCs in-
itiating the formation of dendrites on day 7 after culture 
(Fig. 1). The phenotype of the DCs was confirmed to be that 
of mature DCs by flow cytometry (Fig. 2). Mature DCs have 
a higher CD83 and CD86 count than do immature DCs.
2. Acquisition of tumor-fused DCs
Apoptosis was induced at a ratio of 10±2%. By use of flow 
cytometry, tumor-fused DCs were obtained at a ratio of 
20.3±3% (Fig. 3).
3. Mixed lymphocyte reaction
The amount of BrdU that was used to measure the pro-
liferation of T-lymphocytes showed an absorption rate of 
0.32±0.02 (143%) in the group of DCs sensitized by using 
tumor lysates compared with the T cell single group as the 
control. In the group of tumor-fused DCs, the absorption 
rate was 0.67±0.07 (297%; p＜0.05) (Fig. 4).
4. Measurement of cytokines
The concentration of IL-12 was 6.3±0.16 pg/ml (range, Korean J Urol 2010;51:139-144
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6.1-6.5 pg/ml), 25.3±0.25 pg/ml (range, 25.1-25.6 pg/ml), 
and 55.6±0.19 pg/ml (range, 55.3-55.8 pg/ml) in the DC sin-
gle group, tumor lysate sensitized group, and DC-tumor fu-
sion group, respectively (Fig. 5).
　The concentration of IFN-γ was 15±1.22 pg/ml (range, 
13.5-16.5 pg/ml), 40±1.70 pg/ml (range, 38-42 pg/ml), and 
92.5±0.79 pg/ml (range, 91.5-93.5 pg/ml) in the DC single 
group, tumor lysate sensitized group, and DC-tumor fusion 
group, respectively (Fig. 6).
5. Comparison of cytotoxicity
The concentration of LDH was 1,532 relative fluorescence 
units (RFU) in the group in which DCs were solely cultured, 
2,483.2 RFU in the group in which DCs were sensitized 
with tumor lysates, and 3,923.8 RFU in the group in which 
DCs were fused with tumor cells (Fig. 7).
DISCUSSION
DCs are potent antigen-presenting cells able to induce pri-
mary immune responses. DCs capture and process anti-
gens into peptides. DCs then present the antigens to T cells 
and B cells through MHC class I and II molecules [3]. 
Peptides, proteins, DNA and RNA coding these antigens, 
and tumor lysates have been used to sensitize DCs [4]. An 
alternative approach to increasing antitumor immunity is 
the use of fusions of DCs and tumor cells [12]. In this ap-
proach, a broad spectrum of tumor-associated antigens, in-
cluding those known and unidentified, are processed endo-
genously and presented by MHC class I and II pathways 
in the context of co-stimulatory signals.
　A major issue for the application of DC-tumor cell fusion 
vaccines is the development of compatible and reprodu-
cible procedures that can be readily translated to the clin-
ical setting. Of equal concern is the availability of sufficient 
tumor material for the preparation of tumor cells. In this 
study, we integrated several features important for the 
clinical development of DC-tumor cell fusion vaccines:
(1) a simple process for the generation of DCs, (2) PEG pro-
tocols that permit fusion of sufficient numbers of DCs and 
tumor cells, and (3) the application of tumor cells derived 
from allogenic cell lines.
　In the past, it was difficult to purely isolate DCs and to 
culture them in a massive amount. It has been reported, 
however, that DCs can effectively be cultured in massive 
amounts from human bone marrow, fetal cord blood CD34+ 
hematopoietic stem cells, and CD14＋  monocytes present 
in the peripheral blood [13-16]. Methods for producing tu-
mor fusion vaccines include PEG and electrical stimulation 
[17]. Compared with electrical stimulation, for which spe-
cific types of equipment are required, the PEG methods are 
relatively simpler. In comparison with the reported fusion 
rate, they are also cost-effective.
　In our study, the rate of observed allogenic DC-tumor cell 
fusion vaccines generated by PEG protocols was 20.3±3%. 
This rate was relatively lower than other previous reports 
using PEG. In general, the fusion rate has been reported 
to be 12% to 60% [17,18]. According to Lundqvist et al, fol-
lowing an experiment using three different types of HRPC 
cell lines, there was a consistently higher degree of treat-
ment response, compared with non-hormone-dependent 
cells, in tumor fusion vaccines that were prepared by using 
a single type of cell line [18]. These findings may be evidence 
that the same immune responses might also occur in pa-
tients with HRPC who are assumed to have an equivalent 
degree of antigenicity in the clinical application of allogenic 
tumor-fused cell vaccines.
　Our study applied pre-irradiated tumor cells to induce 
apoptosis in fusion vaccine preparations; radiation doses 
varied between 30 Gy and 200 Gy. Increasing doses of irra-
diation would induce higher levels of apoptosis, and 
high-level cell death has been observed in populations of 
DU 145 cells over time after exposure to 200 Gy. Determin-
ation of an appropriate radiation dose is necessary, espe-
cially because tumor cells are well known to display varia-
bility in their radiosensitivity. In this study, the 150 Gy 
dose was the most effective for the DC-DU 145 cell fusion 
vaccine.
　Concentrations of IL-12 and IFN-γ were measured to be 
more than two times higher to a statistically significant ex-
tent in group 3 than in group 2. These results well illus-
trated that DCs and tumor-specific T cells stimulated with 
DC-tumor fusion had a higher degree of functional activity. 
We used the LDH assay in the cytotoxic test, which con-
firmed a substantial extent of tumor cell destruction. 
Compared with the control group, the cytotoxic results in 
group 2 and group 3 were statistically significant. In partic-
ular, cytotoxicity was significantly higher in group 3 than 
in group 2. In group 1, nonsensitized DCs might hinder 
rather than help the proliferation of T cells. The absorption 
rate of BrdU was 0.19±0.02 (84.1%) lower than in the con-
trol group.
CONCLUSIONS
The DC-tumor fusion rate in our study was 20.3%, which 
is lower than that of other reports. The DC-tumor fusion 
vaccine was functionally active and more effective in stim-
ulating DCs and T cells in HRPC cells than were DCs sensi-
tized with tumor lysate. The DC-tumor fusion vaccine was 
also superior to tumor lysate-sensitized DCs for the cyto-
toxicity of HRPC cells. We suggest the possibility of treat-
ment with the allogenic tumor fusion vaccine in prostate 
cancer in which there is a lower degree of variability in tu-
mor antigens. Further experimental studies are war-
ranted to obtain higher rates of fusion for clinical appli-
cation. In addition, other attempts such as the manipu-
lation of cofactors should be made to further enhance the 
functional activity of DCs.
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